Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Sionna Therapeutics, Inc.NASDAQ: SION
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit turns negative
Q1 FY2026 gross profit was -$154K, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$453K.
Context
- Gross profit increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly gross profit holds near -$154K or moves back toward the trailing-twelve-month quarterly average of -$113.25K.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- (647K) USD
- Year-over-year change
- +3.1%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (647K) | +3.1% |
| FY2024 | 2024-12-31 | (668K) | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Gross Profit vs competitors
How SION compares with its peers on the latest reported figures
- SION's LTM Mar 2026 gross profit of -$453K is the 7th highest of the 11 companies compared; the peer median is $5.85M.
- Its year-over-year change of -172.9% is the lowest of 9, against a peer median of +39.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $393.18M | +29.0% | +96.5% | 91.9% | |
| LTM Mar 2026 | $256.89M | +42.5% | +39.6% | 81.6% | |
| LTM Sep 2026 | $182.57M | +35.8% | -36.4% | 68.6% | |
| LTM Mar 2026 | $18.41M | -89.0% | — | 92.0% | |
| LTM Mar 2026 | $11.7M | +129.7% | +0.9% | 54.1% | |
| LTM Jun 2026 | $0 | — | — | — | |
| LTM Mar 2026 | -$453K | -172.9% | — | — | |
| LTM Sep 2026 | -$742K | +99.6% | — | 662.5% | |
| LTM Sep 2026 | -$753K | +98.1% | — | — | |
| LTM Jun 2026 | -$2.07M | — | — | — | |
| LTM Sep 2026 | -$12.67M | -135.9% | -52.0% | 18.7% | |
| Peer median (excluding SION) | $5.85M | +39.1% | +0.9% | 81.6% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 668K | 647K |
| Gross Profit | 0 | 0 | (668K) | (647K) |
| Gross Margin | — | — | — | — |
| Research & Development | 34.61M | 40.63M | 57.29M | 60.26M |
| Selling, General & Admin | 6.77M | 9.71M | 13.27M | 28.72M |
| Operating Expenses | 41.37M | 50.33M | 69.89M | 88.34M |
| Depreciation & Amortization | 122K | 583K | 668K | 647K |
| EBITDA | (40.12M) | (46.68M) | (61.02M) | (74.62M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (41.37M) | (50.33M) | (70.56M) | (88.98M) |
| Operating Margin | — | — | — | — |
| Interest Income | 1.13M | 2.77M | 8.17M | 13.3M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.13M | 3.07M | 8.87M | 13.71M |
| Income Before Tax | (40.24M) | (47.26M) | (61.69M) | (75.27M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (40.24M) | (47.26M) | (61.69M) | (75.27M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.91) | (1.07) | (1.40) | (1.88) |
| EPS (Diluted) | (0.91) | (1.07) | (1.40) | (1.88) |
| Weighted Avg Shares | 44.12M | 44.12M | 44.12M | 39.96M |
| Weighted Avg Shares (Diluted) | 44.12M | 44.12M | 44.12M | 39.96M |
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.